Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Infrastructure ? Clinical Research Sites (U24 Clinical Trial Not Allowed)

The National Institute of Neurological Disorders and Stroke (NINDS) is seeking to expand the NeuroNEXT network by adding new Clinical Research Sites. The award will be a U24 cooperative agreement (not a clinical trial award) that provides infrastructure, expertise, and collaborative opportunities to conduct high‑quality neuroscience clinical trials and biomarker studies in adult and pediatric populations. Although the solicitation is currently a forecast (applications not yet being accepted), potential applicants are encouraged to begin partnership discussions and prepare responsive proposals for the anticipated opening in late 2027. • Funding mechanism: Cooperative Agreement (U24) under CFDA 93.853. • Target applicants: Wide range of public, nonprofit, for‑profit, tribal, and educational entities (see eligibility list). • Expected award timeline: Synopsis posting ≈ Sept 2027, application response ≈ Nov 2027, award ≈ Jul 2028, project start ≈ Jul 2028. • Scope of work: Provide clinical trial infrastructure, patient recruitment, data management, and biomarker validation capabilities aligned with NeuroNEXT’s network goals. • No cost‑sharing required. • No pre‑bid meeting or site visit required. • Contact: NINDS via email ([email protected]).